Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in Kinshasa

• Status: Completed
• Trial end date: 2020-05-16
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to evaluate the efficacy of hydroxyurea (HU) in improving disease severity in adult patients with sickle cell anemia in Kinshasa (Democratic Republic of Congo). This study aims to:

• assess the safety and efficacy of HU treatment in the Congolese environment;

• assess the reversibility of chronic cardiac lesions. Participants will take hydroxyurea for two years. The effects of the treatment will be evaluated periodically by clinical evaluation, biological tests, and echocardiographic exploration.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Kinshasa
• Collaborator: KU Leuven
• Treatments: Hydroxyurea

Criteria

Inclusion Criteria:

• sickle cell anemia confirmed by DNA testing;

• moderate to severe clinical severity of sickle cell anemia;

• fetal hemoglobin lower than 15%.

Exclusion Criteria:

• poor compliance to follow-up consultation during the observational year

• participant already treated with HU

• pregnant women

• breastfeeding women

• congenital heart disease

• pulmonary disease